Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Equity Average (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Equity Average for 9 consecutive years, with $143.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 773.86% to $143.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $143.9 million, a 773.86% increase, with the full-year FY2025 number at $80.4 million, down 16.03% from a year prior.
  • Equity Average was $143.9 million for Q4 2025 at Rhythm Pharmaceuticals, up from $68.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $366.3 million in Q2 2021 to a low of $3.5 million in Q2 2025.
  • A 5-year average of $177.1 million and a median of $195.5 million in 2023 define the central range for Equity Average.
  • Biggest YoY gain for Equity Average was 773.86% in 2025; the steepest drop was 93.03% in 2025.
  • Rhythm Pharmaceuticals' Equity Average stood at $303.2 million in 2021, then dropped by 10.05% to $272.7 million in 2022, then plummeted by 32.67% to $183.6 million in 2023, then tumbled by 91.03% to $16.5 million in 2024, then soared by 773.86% to $143.9 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Equity Average are $143.9 million (Q4 2025), $68.5 million (Q3 2025), and $3.5 million (Q2 2025).